Table 3. Immunogenicity data at 12 mo post last dose for participants receiving a single dose of HZ vaccine or two doses on a 1-mo or 3-mo schedule, measured using gpELISA, 12-mo per protocol set.
| Single-dose schedule (n = 223) |
Two-dose 1-mo schedule (n = 189) |
Two-dose 3-mo schedule (n = 204) |
|
|---|---|---|---|
|
GMT pre-dose 1 (95% CI) |
241.6 (213.6–273.2) |
217.0 (190.9–246.7) |
227.2 (197.9–260.9) |
|
GMT 12 mo post last dose (95% CI) |
256.3 (229.4–286.4) |
251.1 (223.5–282.3) |
265.2 (235.7–298.5) |
|
GMFR pre-dose 1 to post last dose (95% CI) |
1.06 (0.99–1.14) |
1.16 (1.06–1.26) |
1.17 (1.07–1.27) |
CI, confidence interval; GMFR, geometric mean-fold rise in VZV antibody titers; GMT, geometric mean titer for varicella zoster virus (VZV) antibodies in gpELISA units/mL; gpELISA, enzyme-linked immunosorbent assay using glycoprotein.